

Supplementary Table 8. The risks of any cancer and significant organ-specific cancers in valsartan new users before and after PSM according to NDMA-contaminated valsartan doses

PSM			Colorectal cancer			Pancreatic cancer			Prostate cancer ^{a)}			Stomach cancer		
			Event	aHR (95% CI)	p value	Event	aHR (95% CI)	p value	Event	aHR (95% CI)	p value	Event	aHR (95% CI)	p value
Before PSM ^{b)}	2-year exc.	NDMA-unexposed (mg)							15,521	1.000	-			
		< 10,800							1,336	1.097 (1.037–1.160)	0.001*			
		10,800–40,760							1,365	1.104 (1.044–1.167)	< 0.001*			
		40,800–525,120							1,937	1.126 (1.074–1.181)	< 0.001*			
1:1 PSM ^{c)}	2-year exc.	NDMA-unexposed (mg)	899	1.000	-				1,723	1.000	-	688	1.000	-
		< 10,800	261	1.117 (0.973–1.283)	0.117				490	1.102 (0.996–1.218)	0.060	234	1.355 (1.167–1.572)	< 0.001*
		10,800–40,760	269	1.103 (0.961–1.266)	0.161				495	1.052 (0.951–1.163)	0.330	176	0.996 (0.843–1.177)	0.965
		40,800–525,120	418	1.240 (1.102–1.395)	< 0.001*				764	1.151 (1.056–1.255)	0.001*	290	1.163 (1.011–1.337)	0.034
1:1:1 PSM ^{c)}	2-year exc.	NDMA-unexposed (mg)				560	1.000	-	1,428	1.000	-	551	1.000	-
		< 10,800				169	1.149 (0.966–1.365)	0.116	403	1.093 (0.978–1.221)	0.118	191	1.379 (1.169–1.627)	< 0.001*
		10,800–40,760				178	1.150 (0.969–1.364)	0.109	420	1.071 (0.959–1.195)	0.224	147	1.032 (0.859–1.240)	0.737
		40,800–525,120				239	1.120 (0.960–1.307)	0.150	658	1.178 (1.072–1.294)	< 0.001*	237	1.168 (1.000–1.363)	0.050

PSM, propensity score matching; NDMA, N-nitrosodimethylamine; aHR, adjusted hazard ratio; CI, confidence interval; exc., excluded.

^{a)}All analyses for prostate cancer were performed limited to men.

^{b)}All hazard ratios before PSM were adjusted for age, sex, Charlson comorbidity index, and the year of the first observed valsartan prescription.

^{c)}All hazard ratios after PSM were adjusted for age, sex, and the year of the first observed valsartan prescription.

*Statistically significances at the threshold using Bonferroni correction for 5 tests ($p < 0.01$).